Corrigendum: MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways

Xu Zhang; Jie Wang; Yifeng Wang; Guanzheng Liu; Huan Li; Jiefeng Yu; Runqiu Wu; Jun Liang; Rutong Yu; Xuejiao Liu

doi:10.3389/fonc.2022.911817

Corrigendum: MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways

Front Oncol. 2022 Apr 22:12:911817. doi: 10.3389/fonc.2022.911817. eCollection 2022.

Authors

Xu Zhang^{1

2

3}, Jie Wang^{1

2

4}, Yifeng Wang^{1

2}, Guanzheng Liu¹, Huan Li¹, Jiefeng Yu¹, Runqiu Wu¹, Jun Liang², Rutong Yu^{1

2}, Xuejiao Liu^{1

2}

Affiliations

¹ Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, China.
² Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
³ The Graduate School, Nanjing Medical University, Nanjing, China.
⁴ Department of Neurosurgery, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2020.608082.].

Keywords: OTSSP167; glioblastoma multiforme; glioblastoma stem-like cells; maternal embryonic leucine-zipper kinase; targeted therapy.

Publication types

Published Erratum